Table1_Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis.docx
Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.
Methods: PubMed, Embase, Web of Science, CNKI, and Wanfang Data databases were searched from their inception up to March 31, 2021, to obtain studies on ceftazidime-avibactam therapy versus ceftazidime-avibactam-based combination therapy in patients with carbapenem-resistant Gram-negative pathogens. The primary outcome was mortality rate, and the second outcomes were microbiologically negative, clinical success, and the development of resistance after ceftazidime-avibactam treatment.
Results: Seventeen studies representing 1,435 patients (837 received ceftazidime-avibactam-based combination therapy and 598 received ceftazidime-avibactam therapy) were included in the meta-analysis. The results of the meta-analysis showed that no statistically significant difference was found on mortality rate (Petos odds ratio (OR) = 1.03, 95% confidence interval (CI) 0.79–1.34), microbiologically negative (OR = 0.99, 95% CI 0.54–1.81), and clinical success (OR =0.95, 95% CI 0.64–1.39) between ceftazidime-avibactam-based combination therapy and ceftazidime-avibactam therapy. Although there was no difference in posttreatment resistance of ceftazidime-avibactam (OR = 0.65, 95% CI 0.34–1.26) in all included studies, a trend favoring the combination therapy was found (according to the pooled three studies, OR = 0.18, 95% CI 0.04–0.78).
Conclusions: The current evidence suggests that ceftazidime-avibactam-based combination therapy may not have beneficial effects on mortality, microbiologically negative, and clinical success to patients with carbapenem-resistant Gram-negative pathogens. A trend of posttreatment resistance occurred more likely in ceftazidime-avibactam therapy than the combination therapy. Due to the limited number of studies that can be included, additional high-quality studies are needed to verify the above conclusions.
History
References
- https://doi.org//10.1128/aac.02313-19
- https://doi.org//10.1186/s13756-020-00858-8
- https://doi.org//10.1007/s00134-017-4878-x
- https://doi.org//10.1016/s1473-3099(16)30004-4
- https://doi.org//10.1016/j.ijantimicag.2020.106075
- https://doi.org//10.21037/atm.2019.10.40
- https://doi.org//10.1016/j.ijantimicag.2018.11.015
- https://doi.org//10.3390/antibiotics9070388
- https://doi.org//10.1016/j.ijid.2017.09.017
- https://doi.org//10.1128/aac.00528-19
- https://doi.org//10.1016/S1473-3099(17)30228-1
- https://doi.org//10.1128/aac.01165-15
- https://doi.org//10.1080/1120009x.2019.1709363
- https://doi.org//10.19460/j.cnki.0253-3685.2020.12.025
- https://doi.org//10.1007/s40121-020-00288-4
- https://doi.org//10.1128/aac.00449-17
- https://doi.org//10.1016/j.jgar.2020.10.023
- https://doi.org//10.1002/jrsm.1411
- https://doi.org//10.1016/j.ijantimicag.2019.08.025
- https://doi.org//10.1136/bmj.n71
- https://doi.org//10.7759/cureus.13081
- https://doi.org//10.1128/aac.02497-17
- https://doi.org//10.1007/s40265-018-0902-x
- https://doi.org//10.1093/jac/dky295
- https://doi.org//10.1136/bmj.i4919
- https://doi.org//10.1128/aac.01964-16
- https://doi.org//10.1093/cid/ciy492
- https://doi.org//10.1093/jac/dkv086
- https://doi.org//10.1093/cid/ciab176
- https://doi.org//10.1093/cid/ciw378
- https://doi.org//10.1007/s40265-013-0013-7
- https://doi.org//10.1186/s13756-020-00872-w
- https://doi.org//10.13461/j.cnki.cja.007150
CC BY 4.0